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Abstract Nucleotide metabolism and signalling is directly
linked to myocardial function. Therefore analysis how diversity
of genes coding nucleotide metabolism related proteins affects
clinical progress of heart disease could provide valuable infor-
mation for development of new treatments. Several studies
identified that polymorphism of AMP deaminase 1 gene
(AMPD1), in particular the common C34T variant of this gene
was found to benefit patients with heart failure and ischemic
heart disease. However, these findings were inconsistent in
subsequent studies. This prompted our detailed analysis of heart
transplant recipients that revealed diverse effect: improved early
postoperative cardiac function associated with C34T mutation
in donors, but worse 1-year survival. Our other studies on the
metabolic impact of AMPD1 C34Tmutation revealed decrease
in AMPD activity, increased production of adenosine and de-
inhibition of AMP regulated protein kinase. Thus, genetic,
clinical and biochemical studies revealed that while long term
attenuation of AMPD activity could be deleterious, transient
inhibition of AMPD activity before acute cardiac injury is
protective. We suggest therefore that pharmacological
inhibition of AMP deaminase before transient ischemic event
such as during ischemic heart disease or cardiac surgery could
provide therapeutic benefit.
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Genetic Analysis of AMP Deaminase Mutations
in Humans and its Impact in Heart Disease
A genetic background to the diversity seen in the clinical
progression of heart disease is well documented. Genetic var-
iants that lead to halted or delayed disease progression are
particularly interesting as they may provide a basis for new
therapies. Genetic diversity in pathways involving nucleotide
metabolism are particularly important due to the latter’s direct
links to myocardial function and metabolic regulation [1].
Several polymorphisms of the AMP deaminase 1 (AMPD1)
gene have been described [2]. The C34T (Glu12Stop) mutation
in exon 2 is by far the most common in the general population
with an allele frequency of 10–14 % [3]. Loh et al. [4] were the
first to describe a benefit of the C34T mutation in patients with
heart disease. This study conducted in a group of 132 patients
with dilated cardiomyopathy demonstrated that the probability
of surviving without transplantation for more than 5 years is 8.6
times greater in patients carrying the C34T allele. Anderson
et al. [5] confirmed a protective effect in ischemic heart disease
demonstrating prolonged survival associated with the C34T
mutation in a prospective study in 450 patients. Another study
by Gastmann et al. [6] conducted in a group of 90 patients with
congestive heart failure demonstrated better prognosis in pa-
tients possessing the C34T AMPD1 mutation. Analysis of a
consecutive group of 390 patients with left ventricular dysfunc-
tion revealed better survival in C34T allele carrier patients
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within a subgroup with ischemic cardiac dysfunction [7]. Other
independent studies demonstrated a beneficial effect of the
C34T mutation on metabolic aspects related to the cardiovas-
cular system such as a lower level of an inhibitor of plasmin-
ogen activator and soluble von Willebrand factor in patients
with coronary heart disease [8]. In contrast, three studies have
indicated a lack or even a deleterious effect of the C34T
AMPD1mutation in patients with heart disease. A large popu-
lation study conducted in 935 post myocardial infarction and
433 heart failure patients with long term follow-up indicated
increased mortality associated with the C34T mutation within
patients with a history of myocardial infarction [9]. A prospec-
tive study in 686 patients with stable congestive heart failure
did not demonstrate any impact of the C34T polymorphism on
tested clinical, biochemical, echocardiographic, radionuclide or
exercise parameters [10]. Analysis of 161 patients undergoing
coronary revascularisation for clinical parameters including
heart failure and cardiac death revealed lack of any impact of
the C34T mutation [11]. In case of C34T polymorphism,
assessment of impact on cardiovascular system could be com-
plicated because this mutation was found to exert deleterious
effects on muscle performance [12]. An interesting observation
was highlighted by Safranow et al. that analysed 97 patients
with coronary artery disease and 104 patients with heart failure
[2]. Frequency of diabetes and obesity was lower in subjects
with C34T mutation (Table 1).
Our own studies have focused on the effects of the C34T
mutation in patients undergoing cardiac surgery, including
transplantation. We demonstrated a remarkably high frequen-
cy of C34T mutation of AMPD1 in 22 cardiac donors with
good cardiac function as compared to 10 donors with
echocardiographically confirmed acute cardiac failure [13,
14]. Donors with healthy hearts had a significantly higher
frequency of C34T mutation also compared to control popu-
lation (n=207). Our recent analysis of 262 cardiac donors and
190 heart transplant recipients [15] highlighted a potential
explanation for the discrepancy of published results by indi-
cating that the C34Tmutation induces diverse effects. While a
protective effect was demonstrated in donor hearts with the
C34T mutation in that they required less inotropic support,
recipients of C34T allele carrying organs had a poorer 1 year
survival. It seems that C34T mutation is protective for donor
organ function in the short term but deleterious in the long
term possibly due to the highly immunogenic post transplant
environment. Consistent with this report we found that among
a group of 153 patients undergoing coronary bypass surgery
with use of cardiopulmonary bypass C34Tcarriers were better
protected from functional deterioration [16]. In a group of
patients without heart failure and with advanced coronary
artery disease postoperative ejection fraction was similar to
preoperative in patients with the C34T mutation while it was
significantly decreased in patients without this mutation.
The C34T mutation of AMPD1 affects not only the heart
system. Long before its cardiovascular associations were ob-
served, the C34T mutation was identified as cause of skeletal
myopathy [17, 18]. Homozygotes for this mutation could have
complete loss of AMP deaminase activity in skeletal muscle.
It has been described as one of the most common inherited
metabolic defects, with an estimated allele frequency of 20 %.
Clinical symptoms associated with this deficiency are highly
variable. While many subjects are asymptomatic others suffer
from early fatigue, cramps and/or myalgia. Inability to
Table 1 Summary of clinical ef-
fects of C34T mutation of AMP
deaminase in heart disease
Number of
patients
Diagnosis Effect of C34T mutation Reference
132 dilated cardiomyopathy improved survival [4]
450 ischemic heart disease improved survival [5]
90 congestive heart failure better prognosis [6]
390 left ventricular dysfunction better survival in ischemic
cardiac dysfunction group
[7]
109 coronary artery disease lower level of inflammation/
thrombosis markers
[8]




686 stable congestive heart failure no effect [10]
161 coronary revascularisation no effect [11]
32 heart transplantation high frequency in donors with good
cardiac function
[13, 14]
262 heart transplantation lower need for postoperative
inotropic
support, worse 1 year survival
[15]
201 coronary artery disease or heart
failure
lower prevalence of diabetes [2]
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maintain energy equilibrium, depletion of the muscle nucleo-
tide pool or insufficient supply of anaplerotic substrates for the
Krebs cycle in the exercising skeletal muscle were proposed
as the underlying mechanisms of this syndrome. A varying
effect of this mutation is known to be caused by alternative
splicing of the AMPD1 gene involving the elimination of the
C34T nonsense mutation in exon 2 and allowing production
of functional enzyme [17, 19].
Taken together these data suggest that the C34T mutation of
AMPD1 has diverse effects on the cardiovascular system and
on the function of the human organism as a whole. During
acute cardiovascular incidents it is clearly beneficial, but in the
long term and in highly immunogenic environments such as
after transplantation, the C34T mutation may have deleterious
effect. Discrepancies between different studies attempting to
clarify the impact of this alteration on human longevity may be
a consequence of a different interplay of beneficial and delete-
rious effects in specific clinical conditions and under specific
treatment. Besides basic information these studies have provid-
ed a clear indication when and how a potential therapy based on
AMPD inhibition could be applied clinically.
AMP Deaminase Isoforms and its Expression Pattern
in the Heart
AMP-deaminase (AMPD) exists in human tissues in several
isoforms with different kinetic properties, molecular weights
and structures. These isoforms are the products of three dif-
ferent genes: AMPD1, AMPD2 and AMPD3. In humans
AMPD1 is predominantly expressed in skeletal muscle,
AMPD2 is predominantly expressed in the brain, liver and
heart and AMPD3 is expressed mainly in the erythrocytes. In
rodents the expression pattern of these three isoforms is dif-
ferent. While AMPD1 is still the dominant skeletal muscle
isoform and AMPD2 is present in the liver, AMPD3 is almost
exclusively expressed in the heart [20]. This indicates that
altered expression of AMPD1 (as conferred by the C34T
mutation) would not have any effect on AMPD expression
in the mouse or rat heart. In humans the situation is very
complex. While AMPD2 is the main form expressed in human
myocardium, transcripts for AMPD3 and AMPD1 are also
present (our unpublished observations). Therefore the
AMPD1 C34T mutation has an impact not only on skeletal
muscle AMPD activity but also on its activity in myocardium
where it causes a substantial reduction in enzyme activity even
among heterozygotes [21, 22].
AMP Deaminase Metabolic Function
AMP deaminase is an enzyme involved in the breakdown of
nucleotides. It has several unique cellular functions and its
activity and expression pattern are highly tissue specific. It
plays a particularly important role in the breakdown of nucle-
otides in skeletal muscle. AMP deaminase forms part of the
purine nucleotide cycle, which is designed to preserve
adenylate’s energy charge and phosphorylation potential un-
der conditions of insufficient energy supply. This cycle plays a
crucial role in regulating the adenine nucleotide pool, in the
synthesis of guanine nucleotides and in the provision of
anaplerotic substrates for the Krebs cycle. These processes
are important in skeletal muscle so the activity of AMP
deaminase is 30–100 times higher than in the other organs.
Under conditions of heavy exercise, when AMP accumulates,
AMP deaminase allows rapid breakdown of AMP to IMP
allowing a higher value of phosphorylation potential and free
energy from ATP hydrolysis that translates directly into im-
proved exercise capacity to be maintained. After exercise,
when energy use is decreased, the IMP (a polar molecule) that
remained inside the cell is reincorporated back into the ade-
nine nucleotide pool via the adenylosuccinate synthetase and
adenylosuccinate lyase reactions. The latter reaction also re-
leases fumarate that supports the operation of the Krebs cycle.
In the heart and non-muscle organs AMP deaminase is not
involved in the purine nucleotide cycle, but plays a role in
regulation of the adenine nucleotide pool and in the synthesis
of guanine nucleotides. The contribution of the AMP deami-
nation pathway to the overall catabolism of nucleotides seems
to be lower in human cardiomyocytes than in rat
cardiomyocytes [23, 24], but still accounts for 30 % of the
total breakdown capacity.
Increased Production of Adenosine due to AMP
Deaminase Deficiency
An important consequence of AMP deaminase deficiency is
an increased flux of substrates through the 5′-nucleotidase
pathway and increased adenosine production under conditions
of heavy exercise. Adenosine content was found to increase
14 times in skeletal muscle biopsies taken from patients with
AMPD deficiency during exercise compared with a 2 fold
increase in normal subjects [25, 26]. The physiological effects
of increased adenosine production in this setting have not
been evaluated. However, previous studies have shown that
increased production of adenosine may ameliorate a number
of pathological processes including those involved in heart
failure [27]. Adenosine has long been recognised to increase
coronary flow and to be involved in the autoregulatory loop
between contractile cells and blood supply [28] and was
classified as an autacoid, retaliating against external stimuli,
which deplete intracellular ATP in the heart [29]. A number of
other cardioprotective physiological effects of adenosine have
been described, such as the antagonism of catecholamine
mediated hypercontraction, an anti-aggregatory activity, the
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inhibition of adhesion and toxic free radical generation by
polymorphonuclear leukocytes, the promotion of angiogene-
sis and the induction of preconditioning [30–34]. Adenosine
inhibits T lymphocyte function both at the stage of blastic
transformation and cytolysis [35–40]. Increased adenosine
concentration is partially responsible for severe combined
immunodeficiency syndrome observed in patients with
inherited adenosine deaminase deficiency. These immunosup-
pressive effects are of particular interest during transplanta-
tion. Adenosine also affects several processes involved in the
pathogenic mechanisms of heart failure such as TNFα and IL-
6 production [41–44], apoptosis [45] and proliferation of
fibroblasts and smooth muscle cells [46–50]. We have previ-
ously shown the significant capacity of human endothelial
cells to degrade AMP via the deamination pathway [51]. An
increased adenosine production in cardiac endothelial cells
due to deficiency of AMPD is one possible mechanism of
the cardioprotective effects. However, even changes in remote
organs may equally exert beneficial cardiac effects. Precondi-
tioning at a distance has been demonstrated, indicating that an
increase in adenosine production outside the heart in skeletal
muscle for example may exert beneficial cardiac effects [52].
It has been shown also that a period of brief myocardial
ischemia and increased cardiac adenosine production are ca-
pable of attenuating platelet aggregation in remote arteries
[53]. Treatment with A2 adenosine receptor agonists was
found to exert beneficial effects in animal models of both
acute and chronic heart failure [54].
Despite numerous reports indicating benefits of elevated
adenosine in cardiovascular disease, caution is needed as
some studies demonstrated deleterious effects. The
AMISTAD trial reported reduced infarct size but increased
number of adverse clinical events, including death, in patients
infused with adenosine as an adjunct to thrombolysis [55].
The administration of adenosine could be proarrhythmic [56]
or produce coronary artery steal phenomenon in patients with
critical stenosis [57]. Besides cardiovascular effects adenosine
can contribute to fluid-retaining disorders via its A1 receptor
mediated effects in the kidney [58] or induce bronchospasm in
some patients [59]. Adenosine effects on immune cell func-
tion mediated by purinergic receptors may also promote can-
cer progression [60]. While these deleterious effects are re-
stricted to specific clinical scenarios, its careful monitoring is
needed in any adenosine related therapy including potential
treatment with AMPD inhibitors.
Activation of AMP Regulated Protein Kinase by AMP
Deaminase Inhibition
AMP is not only a substrate for the AMPD reaction but also an
allosteric regulator that signals energy deficiency in the cell.
AMP directly activates glycolytic enzymes and indirectly
controls a broad range of cellular functions via AMP regulated
protein kinase (AMPK). AMPK is a heterotrimeric protein that
was initially described as a regulator of energy metabolism [61,
62] but later found to play a role in cytoprotection, cell growth
and regeneration [63]. The metabolic role of AMPK includes
activation of fatty acid transport into themitochondria—accom-
plished by phosphorylation and inhibition of acetyl CoA car-
boxylase—and reduction of malonyl-CoA concentration.
AMPK activates glucose transport into the cell by translocation
of GLUT-4 into the membrane and controls the expression of
enzymes of energy metabolism by phosphorylation of HIF-1.
Besides its metabolic effects, AMPK is linked with the Akt
kinase pathway and induction of proteins involved in
cytoprotection and regeneration. Activation of AMPK in heart
infarction or heart failure is currently considered as a therapeu-
tic target [64]. AMPK is also believed to be activated by
commonly used drugs such as metformin [65]. However,
AMPK’s protective effects could be dependent on how and
when it is activated [66]. Loss of regulatory feedback in AMPK
due to mutation in its γ2 subunit (PRKAG2) resulting in
constitutively increased activity is known to cause myocardial
glycogen storage disease and cardiomyopathy [67–69]. Our
current hypothesis is that inhibition of AMPD will act to
amplify the AMP accumulation in cells with disrupted energy
metabolism. This indirect AMPK activation by its endogenous
activator could be superior to direct activation of AMPK (e.g.
by AICAr) since AMPK activation would be restricted to cells
and conditions where this activation is necessary. We have
in vitro evidence showing that high AMPD activity could
suppress AMPK activity, possibly by competition for AMP.
Recent study on the mechanism of AMPK activation by met-
formin has suggested involvement of inhibition of AMPD [70].
Inhibition of AMP Deaminase as a Therapeutic Strategy
We have developed several possible therapeutic strategies
based on the beneficial effects of adenosine that are applicable
during cardiac surgery. We have established that adenosine
administration both as a constituent of cardioplegic solution
or as an infusion following cardioplegic arrest is beneficial [71,
72]. Administration of adenosine at the time of cardioplegic
arrest, after reperfusion or after myocardial infarction is under-
going clinical evaluation. We have also developed a procedure
that allows endogenous adenosine production in normoxic
cardiac cells to increase by combined application of adenosine
metabolism inhibitors and substrates for nucleotide synthesis
[73]. We have shown that application of this procedure follow-
ing experimental transplantation resulted in an improvement in
all aspects of cardiac mechanical function, roughly a threefold
decrease in postischemic cardiac neutrophil infiltration and an
increase in myocardial ATP concentration. The discovery that
genetic alterations of nucleotide metabolism that potentially
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leads to enhanced adenosine production and result in improved
clinical outcome in heart dysfunction indicates new areas
where such treatment could be applied.
The limited availability of specific inhibitors of AMPD is a
major drawback for testing the regulation of AMPD in heart
disease. Such inhibitors are not commercially available, al-
though a procedure for chemical synthesis has been described
[74] and preliminary evaluation of their effects has been per-
formed as part of a PhD thesis [75]. We have followed this
procedure and chemically synthesized a most effective com-
pound: 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydrona-
phthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1, 3]diazepin-8-
ol (AMPDI). We have performed several preliminary studies
using AMPDI with isolated AMPD, with heart homogenates, in
isolated rat cardiomyocytes, perfused hearts and in mice in vivo
[76–78]. In each case the efficiency of AMPD inhibition was
confirmed, although in cardiomyocytes, perfused hearts and
in vivo the concentration of inhibitor had to be several orders
of magnitude higher than for isolated enzyme or heart homog-
enate alone. We have established that even at these high con-
centrations AMPDI remained specific for AMPD inhibition.
While further studies are necessary to clarify the difference in
effective concentration we believe that we have optimized the
conditions for in vivo use of AMPDI. We have conducted a
preliminary assessment of AMPDI effects in a mouse model of
cardiac hypoxia and have demonstrated a protective effect [78].
We have established that the half life of AMPDI in mouse blood
is relatively short (about 30 min) and that AMPD inhibition
in vivo is transient, even with continuous infusion. AMPDI
could therefore be a good tool to study the acute effects of
AMPD inhibition, but the design of chemicals suitable for long
term in vivo use and as drug candidates requires further work.
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